5月30日,加科思-B(01167)盘中股价上涨超8%,本周累计涨幅已超25%。其与艾力斯合作开发的KRAS G12C抑制剂戈来雷塞在国内获批上市,用于治疗KRAS G12C突变的非小细胞肺癌患者。此次获批使加科思获得5000万元里程碑付款。目前,加科思正与信达生物、正大天晴等企业在商业化上展开竞争。艾力斯已组建营销团队,推动戈来雷塞尽快纳入国家医保目录,以惠及更多患者。免责声明:本文内容由开放的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.